Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.
|Videos|July 19, 2016
Thoughts on Antibacterial and Antimicrobial Central Line Devices
Author(s)Contagion Editorial Staff
Michael Calderwood, MD, MPH, previously assistant hospital epidemiologist and associate director of antimicrobial stewardship at Brigham and Women’s Hospital, discusses concerns over antibacterial and antimicrobial central line devices.
Advertisement
Michael Calderwood, MD, MPH, previously assistant hospital epidemiologist and associate director of antimicrobial stewardship at Brigham and Women’s Hospital, discusses concerns over antibacterial and antimicrobial central line devices.
Interview Transcript (slightly modified for readability)
“The evidence [regarding the use of antibacterial and antimicrobial central line devices] is still [in its early stages]. We know that [the devices] are in use, and sometimes hospitals will use them for certain devices but not others, just because that’s the way it works via purchasing.
My concerns, as a steward, is whether or not this is going to drive higher rates of resistance and I’m waiting for some better evidence on whether this should be standard practice.”
Advertisement
Related to this article
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Advertisement
Advertisement
Trending on Contagion Live
1
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
2
Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria
3
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
4
Zelicapavir Shortens RSV Symptoms Despite Missing Primary End Point
5